{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:05:25Z","timestamp":1790255125605,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20lm0203139"],"award-info":[{"award-number":["JP20lm0203139"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201332","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:29:36Z","timestamp":1787326176000},"page":"201332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive preclinical evaluation of second-generation miRNA-regulated Coxsackievirus B3-BHP: Potent antitumor efficacy and safety"],"prefix":"10.1016","volume":"34","author":[{"given":"Yuki","family":"Sakashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyako","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Momoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzaburo","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-2199","authenticated-orcid":false,"given":"Mutsunori","family":"Murahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201332_bib1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2026.201332_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2026.201332_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ags3.12270","article-title":"Multidisciplinary oncolytic virotherapy for gastrointestinal cancer","volume":"3","author":"Fujiwara","year":"2019","journal-title":"Ann. Gastroenterol. Surg."},{"key":"10.1016\/j.omton.2026.201332_bib4","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201332_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201332_bib6","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201332_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","article-title":"Talimogene laherparepvec: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.omton.2026.201332_bib8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201332_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene firadenovec: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omton.2026.201332_bib10","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1200\/JCO.20.03246","article-title":"Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma","volume":"39","author":"Andtbacka","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201332_bib11","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","article-title":"Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201332_bib12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ijc.20866","article-title":"Oncolysis of human ovarian cancers by echovirus type 1","volume":"115","author":"Shafren","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2026.201332_bib13","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","article-title":"Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma","volume":"72","author":"Miyamoto","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201332_bib14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.omto.2019.01.003","article-title":"Extremely low organ toxicity and strong antitumor activity of miR-34-regulated oncolytic coxsackievirus B3","volume":"12","author":"Jia","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201332_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.21873\/anticanres.14753","article-title":"Development of new oncolytic virotherapy targeting breast cancer using coxsackievirus B3","volume":"41","author":"Sagara","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2026.201332_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/cdd.2009.56","article-title":"The miR-34 family in cancer and apoptosis","volume":"17","author":"Hermeking","year":"2010","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.omton.2026.201332_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.molcel.2007.05.010","article-title":"Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis","volume":"26","author":"Chang","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2026.201332_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCRESAHA.117.305962","article-title":"MicroRNA-34a plays a key role in cardiac repair and regeneration following myocardial infarction","volume":"117","author":"Yang","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.omton.2026.201332_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature11919","article-title":"MicroRNA-34a regulates cardiac ageing and function","volume":"495","author":"Boon","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201332_bib20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jacc.2008.10.064","article-title":"Cardiac deletion of the coxsackievirus-adenovirus receptor abolishes coxsackievirus B3 infection and prevents myocarditis in vivo","volume":"53","author":"Shi","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.omton.2026.201332_bib21","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1128\/JVI.00857-06","article-title":"Novel fiber-dependent entry mechanism for adenovirus serotype 5 in lacrimal acini","volume":"80","author":"Xie","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201332_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2014.12.017","article-title":"Tear-mediated delivery of nanoparticles through transcytosis of the lacrimal gland","volume":"208","author":"Hsueh","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omton.2026.201332_bib23","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.7150\/ijms.50248","article-title":"MicroRNA expression profile of lacrimal glands in rabbit autoimmune dacryoadenitis model","volume":"17","author":"Liu","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.omton.2026.201332_bib24","first-page":"4191","article-title":"Mechanisms involved in injury and repair of the murine lacrimal gland","volume":"53","author":"Gromova","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omton.2026.201332_bib25","first-page":"569","article-title":"Mechanisms of murine lacrimal gland repair after experimentally-induced injury","volume":"15","author":"Gromova","year":"2017","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.omton.2026.201332_bib26","first-page":"8440","article-title":"Interleukin-1\u03b2-induced chronic viral myocarditis in coxsackievirus B3-infected mice: the role of CD8+ T cells","volume":"72","author":"Huber","year":"1998","journal-title":"J. Vir."},{"key":"10.1016\/j.omton.2026.201332_bib27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2353\/ajpath.2008.071008","article-title":"Sex differences in autoimmune disease from a pathological perspective","volume":"173","author":"Fairweather","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omton.2026.201332_bib28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201332_bib29","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926002080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926002080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:37:20Z","timestamp":1790253440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926002080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926002080"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201332","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive preclinical evaluation of second-generation miRNA-regulated Coxsackievirus B3-BHP: Potent antitumor efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201332"}}